Salarius Pharmaceuticals, Inc. filed an 8-K on October 6, 2025, reporting that it has until October 20, 2025, to show it has at least $2.5 million in stockholders' equity, which it believes it has achieved through recent stock issuance totaling approximately $6.2 million.